Supportive Care

Strategies for Using Anticoagulation Therapy in Patients With Cancer

Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates...

Issues in Oncology
Legislation

AACR Releases Annual Cancer Progress Report

The American Association for Cancer Research (AACR) has released its annual Cancer Progress Report,1 highlighting how federally funded research discoveries are fueling the development of new and...

Lung Cancer

Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC

In April 2018, osimertinib (Tagrisso) was approved for the first-line treatment of metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon...

 


Advertisement
Hematologic Malignancies
Lymphoma

Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma

In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no...

 

Hematologic Malignancies

Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL

Advances in cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant...

 


More Top Stories

Solid Tumors

Apostolia-Maria Tsimberidou, MD, PhD, on Precision Medicine: Results From the IMPACT Study

A Pathologic Fascination With Humanity

The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Advertisement

Genomic Classification of Myeloproliferative Neoplasms and Integration in Predictive Models

In a study reported in The New England Journal of Medicine, Grinfeld et al identified distinct genomic subgroups among patients with myeloproliferative neoplasms that, when combined with clinical variables, offered the potential for individualized predictions of clinical outcomes. Study Details...

Issues in Oncology
Pain Management

Jay B. Shah, MD, on Reducing Opioid Use After Urologic Oncology Surgery

Vamsidhar Velcheti, MD, Joins NYU Langone as Director of Thoracic Medical Oncology

Clinician and researcher Vamsidhar ‘Vamsi’ Velcheti, MD, recently joined the Perlmutter Cancer Center at New York University (NYU) Langone Health as Director of Thoracic Medical Oncology. He aims to improve clinical care, increase translational and clinical research, and promote interdisciplinary ...

Issues in Oncology

Monthly Vitamin D and Cancer Risk

In a study reported in JAMA Oncology, Robert Scragg, MBBS, PhD, of the School of Population Health, University of Auckland, and colleagues found that monthly high-dose vitamin D supplementation, without calcium, was not associated with a reduced risk of developing cancer. The current analysis is ...

Established, Modifiable Cancer Risk Factors

According to a new American Cancer Society report published by Gapstur et al in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the expansion of tobacco control—the intervention with the largest potential health benefits. This report is the...

Hematologic Malignancies
Immunotherapy

Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

ASH Honors Ross L. Levine, MD, With 2018 William Dameshek Prize

The American Society of Hematology (ASH) will present the 2018 William Dameshek Prize to Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, for his discoveries in the field of leukemia and myeloproliferative neoplasms during the 2018 ASH Annual...

Advertisement

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma

In an analysis of two Nordic Lymphoma Group trials with long-term follow up reported in the Journal of Clinical Oncology, Lockmer and colleagues found evidence that many patients receiving rituximab (Rituxan) as initial treatment for advanced indolent lymphoma may not require the addition of...


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.